Risk factor | Relative risk (RR) (other statistics are noted when used) |
Increasing age | 1 to 2% cumulative incidence of endometrial cancer in females age 50 to 70 years |
Unopposed estrogen therapy | 2 to 10 |
Tamoxifen therapy | 2 |
Early menarche | NA |
Late menopause (after age 55) | 2 |
Nulliparity | 2 |
Polycystic ovary syndrome (chronic anovulation) | 3 |
Obesity | For type I endometrial cancer: OR 1.5 for overweight (BMI 25.0 to <30 kg/m2), 2.5 for class 1 obesity (30.0 to <35 kg/m2), 4.5 for class 2 obesity (35.0 to 39.9 kg/m2), and 7.1 for class 3 obesity (≥40.0 kg/m2). For type II: OR 1.2 for overweight (BMI 25.0 to <30 kg/m2), 1.7 for class 1 obesity (30.0 to <35 kg/m2), 2.2 for class 2 obesity (35.0 to 39.9 kg/m2), and 3.1 for class 3 obesity (≥40.0 kg/m2). |
Diabetes mellitus | 2 |
Estrogen-secreting tumor | NA |
Lynch syndrome (hereditary nonpolyposis colorectal cancer) | 13 to 71% lifetime risk |
Cowden syndrome | 13 to 28% lifetime risk |
Family history of endometrial, ovarian, breast, or colon cancer | NA |
Do you want to add Medilib to your home screen?